Skip to main content
European Commission logo print header

Pharmaceutical Open Innovation Test Bed for Enabling Nano-pharmaceutical Innovative Products

Project description

A platform for bringing nanopharmaceuticals to bedside

Advances in nanotechnology have found applications in the pharmaceutical industry, positively impacting patients and society in general. To further enhance the growth and innovation capacity of nanotechnology, testing and manufacturing facilities must be improved. The EU-funded Phoenix project aims to facilitate the translation of nanopharmaceuticals from bench to bedside through the establishment of an open innovation test bed (OITB) that complies with regulatory and good manufacturing practice guidelines. Phoenix-OITB will consist of a network of facilities, technologies, services and technology transfer expertise to expedite the production and commercialisation of nanopharmaceuticals.

Objective

Nano-pharmaceuticals have the potential to drive the scientific and technological uplift, offering great clinical and socio-economic benefits to the society in general, industry and key stakeholders and patients. Nevertheless, affordable and advanced testing, manufacturing facilities and services for novel nano-pharmaceuticals are main prerequisites for successful implementation of these advances to further enhance the growth and innovation capacity. The establishment of current good manufacturing practice (cGMP) in nano-pharmaceutical production at large scale is the key step to transfer successfully the nano-pharmaceuticals from bench to bedside (from lab to industrial scale). Due to the lack of resources to implement GMP manufacturing at-site, the upscaling and production of innovative nano-pharmaceuticals is still challenging to main players of EU nanomedicine market, start-ups and SMEs. To allow successful implementation of the nano-pharmaceuticals in the nanomedicine field, there is an urgent need to establish science- and regulatory-based Open Innovation Test Bed (OITB). Phoenix aims to enable the seamless, timely and cost-friendly transfer of nano-pharmaceuticals from lab bench to clinical trials by providing the necessary advanced, affordable and easily accessible Phoenix-OITB. Phoenix-OITB will offer a consolidated network of facilities, technologies, services and expertise for all the technology transfer aspects from characterization, testing, verification up to scale up, GMP compliant manufacturing and regulatory guidance. Phoenix-OITB will develop and establish new facilities and upgrade existing ones to make them available to SMEs, starts-up and research laboratories for scale-up, GMP production and testing of nano-pharmaceuticals. The services and expertise provided by the OITB will include production and characterization under GMP conditions, safety evaluation, regulatory compliance and commercialisation boost.

Keywords

Call for proposal

H2020-NMBP-TO-IND-2018-2020

See other projects for this call

Sub call

H2020-NMBP-TO-IND-2020-twostage

Coordinator

LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY
Net EU contribution
€ 644 001,25
Address
5 AVENUE DES HAUTS FOURNEAUX
4362 Esch Sur Alzette
Luxembourg

See on map

Region
Luxembourg Luxembourg Luxembourg
Activity type
Research Organisations
Links
Total cost
€ 644 001,25

Participants (11)